Grace Therapeutics (GRCE) Liabilities and Shareholders Equity (2017 - 2026)
Grace Therapeutics' Liabilities and Shareholders Equity came in at $50.07 million for fiscal Q1 2027 (quarter ended Jun 30, 2026), down 28.3% from $69.81 million a year earlier and down 24.9% from the prior quarter.
Powered by 
Analysis
Grace Therapeutics (GRCE) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
At the end of FY2026 (ended Mar 31, 2026), Grace Therapeutics' Liabilities and Shareholders Equity was $66.65 million, down 7.4% from FY2025.
- Liabilities and Shareholders Equity has declined in each of the last four fiscal years, though with a five-year compound annual growth rate of 1.3% (FY2021 to FY2026).
- Going back by fiscal year, Liabilities and Shareholders Equity was $71.99 million in FY2025 (-1.8%), $73.3 million in FY2024 (-7.4%), $79.12 million in FY2023 (-38.5%) and $128.62 million in FY2022 (+105.9%).
- The fiscal Q1 2027 figure represents the lowest quarterly Liabilities and Shareholders Equity since fiscal Q3 2021.
- Year-over-year, Liabilities and Shareholders Equity increased in three of the last eight quarters, with an average decline of 7.5%.
- The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in fiscal Q2 2022 (growth of 766.1%), and the weakest in fiscal Q1 2024 (a decline of 41.5%).
- Business Quant data shows GRCE's Liabilities and Shareholders Equity at $66.65 million (Q4 2026), $68.49 million (Q3 2026) and $66.58 million (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 142.28 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 201.06 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 135.12 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 129.80 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 122.03 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 115.83 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 95.64 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 49.36 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 201.13 Bn |
| 10 | Grace Therapeutics | 34.02 Mn | -32.25 Mn | - | 50.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 50.07 Mn |
| Mar 31, 2026 | 66.65 Mn |
| Dec 31, 2025 | 68.49 Mn |
| Sep 30, 2025 | 66.58 Mn |
| Jun 30, 2025 | 69.81 Mn |
| Mar 31, 2025 | 71.99 Mn |
| Dec 31, 2024 | 61.22 Mn |
| Sep 30, 2024 | 65.35 Mn |
| Jun 30, 2024 | 69.72 Mn |
| Mar 31, 2024 | 73.30 Mn |
| Dec 31, 2023 | 76.19 Mn |
| Sep 30, 2023 | 78.21 Mn |
| Jun 30, 2023 | 73.03 Mn |
| Mar 31, 2023 | 79.12 Mn |
| Dec 31, 2022 | 116.80 Mn |
| Sep 30, 2022 | 120.91 Mn |
| Jun 30, 2022 | 124.93 Mn |
| Mar 31, 2022 | 128.62 Mn |
| Dec 31, 2021 | 114.23 Mn |
| Sep 30, 2021 | 119.80 Mn |
API Access
Grace Therapeutics Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=GRCE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "GRCE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=GRCE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();